InvestLog
NTRB logo

NTRB

Nutriband Inc.NASDAQHealthcare
$3.63+0.83%ClosedMarket Cap: $44.2M

As of 2026-04-06

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.96

P/S

19.93

EV/EBITDA

-3.22

DCF Value

$-3.13

FCF Yield

-12.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

32.6%

Operating Margin

-406.5%

Net Margin

-560.8%

ROE

-185.4%

ROA

-151.8%

ROIC

-118.6%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 2025$346.1K$-3.9M$-0.32
Q2 2025$622.5K$-2.0M$-2.12
Q1 2025$667.4K$-1.4M$-0.12
Q4 2024$642.4K$-5.5M$-0.51

Trading Activity

Insider Trades

View All
Sheridan Garethdirector, 10 percent owner, officer: Chief Executive Officer
SellTue Nov 25
Sheridan Garethdirector, 10 percent owner, officer: Chief Executive Officer
SellTue Nov 25
Sheridan Garethdirector, 10 percent owner, officer: Chief Executive Officer
SellTue Nov 25
Goodman Geraldofficer: Chief Financial Officer
SellTue Oct 21
Goodman Geraldofficer: Chief Financial Officer
SellTue Oct 21

Company Info

Sector

Healthcare

Industry

—

Country

US

Exchange

NASDAQ

Beta

1.93

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Peers

ACETACRVADAGCRVOFBIOGANXLITSRLMD